Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401933 · ClinicalTrials.gov registry record · Phase 1
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT01401933 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Abbott. The registered enrollment target is 14 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01401933, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, open-label study designed to determine the interaction of rifampin with linifanib.
Conditions Studied
Interventions
- DRUG Rifampin
- DRUG Linifanib
Study Locations (2)
Arizona
- Site Reference ID/Investigator# 49953 - Tucson
Wisconsin
- Site Reference ID/Investigator# 49952 - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401933
The ClinicalTrials.gov registry entry for NCT01401933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Rifampin is the first listed.
NCT01401933 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01401933 about?
NCT01401933 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors". This is a phase 1, open-label study designed to determine the interaction of rifampin with linifanib.
What is the current status of trial NCT01401933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-05. Estimated completion is 2011-10.
What conditions does trial NCT01401933 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT01401933?
The interventions under investigation include: Rifampin (DRUG), Linifanib (DRUG).
Who is sponsoring clinical trial NCT01401933?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01401933 being conducted?
This trial has 2 study locations across Arizona, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.